Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is currently evaluating mavorixafor in a Phase 3 clinical trial in chronic neutropenia (CN ...

Q4 2024 Earnings Call Transcript March 25, 2025 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.2 EPS, expectations were $-0.17. Operator: Greetings, and welcome to the ...

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.

In the assessment of 12-month price targets, analysts unveil insights for X4 Pharmaceuticals, presenting an average target of $1.88, a high estimate of $3.00, and a low estimate of $1.50. Consistency ...

$XFOR ($XFOR) is expected to release its quarterly earnings data on Tuesday, March 25th before market open, per Finnhub. Analysts are expecting revenue of $1,061,820 ...

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is currently evaluating mavorixafor in a Phase 3 clinical trial in chronic neutropenia (CN) patients. The 4WARD trial is expected to enroll a total of 150 ...

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of 20 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...